Clinical Trial

Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients

Study acronym: PINTL
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To study the efficacy and safety of pitavastatin and PCSK9 inhibitors in liver transplant patients on ongoing immunosuppressive therapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-09-08; most recent amendment 2025-01-21.
Status change: Recruiting → Active, Not Recruiting 2025-01-21
Trial Details
NCT Number NCT05537948
Lead Sponsor National Medical Research Center for Therapy and Preventive Medicine
Conditions Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder, Immunosuppression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Statins
Enrollment 59 participants
Start Date 2021-10-01
Primary Completion 2024-01-31 (estimated)
Study Completion 2025-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-22